NCT00236587View on ClinicalTrials.gov

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2001

Study Completion Date

February 29, 2004

Conditions
Schizophrenia
Interventions
DRUG

risperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00236587 - A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia | Biotech Hunter | Biotech Hunter